ted: “I am extremely proud to have had the opportunity to join the dynamic team at Biotrial in an R&D role. Today’s environment of developing differentiated drugs that deliver proven patient benefits is more challenging than ever, especially in the CNS domain, so having strong capabilities and expertise in-house is necessary for a CRO to fully meet their clients’ needs. Biotrial Neuroscience has capitalized on broad experience and a solid track record in conducting CNS-focused clinical trials, and with the integration of Forenap’s experienced personnel and equipment, Biotrial Neuroscience now provides more extensive services in the field of Electrophysiology (EEG, ERPs), Sleep studies, Neuroimaging and Pain models.”
Founded in 1989, Biotrial is a leading CRO specialized in Early Development with a wide range of services from Non-Clinical Pharmacology, Phase I studies, Phase II-IV Trial Management, Bioanalysis, Oncology, Data Management, Biostatistics, ECG & Imaging Core Lab (QT/QTc Trials, Psychometric Testing, Imaging, EEG/PSG Assessment), Regulatory Affairs to Medical Writing.
Based in France, Belgium, the United Kingdom, Canada and the United States, Biotrial performs hundreds of studies a year and offers tailor-made solutions to Biotech and Pharmaceutical companies.
For further information please contact Anne Peron on [+33] 029-959-9191 or visit http://www.biotrial.com
Read the full story at http://www.prweb.com/releases/2013/4/prweb10580700.htm.
Page: 1 2 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division2
. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor3
. Another Successful Year at Divine Skin4
. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round5
. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit6
. Spherix Announces Successful Completion of Important Toxicology Study of SPX-1067
. RiverVest Venture Partners Sells Four Successful Life Science Companies for More than $1 Billion8
. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI9
. Successful human tests for first wirelessly controlled drug-delivery chip10
. First successful human results achieved: Implantable wireless microchip drug delivery device11
. Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program